By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synthetic Biologics, Inc. 

3930 Varsity Drive

Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-7800 Fax: 734-332-7878


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Synthetic Biologics (SYN) To Present At The 2016 BIO CEO & Investor Conference 2/3/2016 8:30:20 AM
Synthetic Biologics (SYN) Reports Results Of Independent Third Party Evaluations Of Trimesta Data From Investigator-Sponsored Phase 2 Clinical Trial For Relapsing-Remitting Multiple Sclerosis 2/2/2016 6:04:00 AM
Synthetic Biologics (SYN)'s IBS-C Drug Meets All Endpoints in Second Phase II Study 1/20/2016 5:59:26 AM
Synthetic Biologics (SYN) To Present At The Biotech Showcase 2016 Conference 1/6/2016 10:48:04 AM
Synthetic Biologics, Inc. (SYN)' SYN-010 Lowered Breath Methane And Improved Stool Frequency In A Phase 2 Four Week Study In Patients With Irritable Bowel Syndrome With Constipation (IBS-C) 12/8/2015 11:01:45 AM
Synthetic Biologics, Inc. (SYN) To Webcast Microbiome Clinical Program Seminar 12/7/2015 10:00:36 AM
Synthetic Biologics, Inc. (SYN) Release: Texas Engineers Develop Potential Treatment For Whooping Cough 12/3/2015 11:22:16 AM
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection 12/1/2015 6:18:52 AM
Synthetic Biologics, Inc. (SYN) Reports That Data From The Phase 2 Trimesta Clinical Trial For Relapsing-Remitting Multiple Sclerosis Were Published By Lead Principal Investigator 11/30/2015 6:23:28 AM
Synthetic Biologics, Inc. (SYN) Announces Issuance Of First Key U.S. Patent Directly Covering SYN-010, The Company's Novel Candidate For Irritable Bowel Syndrome With Constipation (IBS-C) 11/24/2015 6:15:46 AM
12345678910...
//-->